175 related articles for article (PubMed ID: 23521541)
1. Oncogenic properties of sphingosine kinases in haematological malignancies.
Wallington-Beddoe CT; Bradstock KF; Bendall LJ
Br J Haematol; 2013 Jun; 161(5):623-638. PubMed ID: 23521541
[TBL] [Abstract][Full Text] [Related]
2. Targeting sphingosine-1-phosphate in hematologic malignancies.
Stevenson CE; Takabe K; Nagahashi M; Milstien S; Spiegel S
Anticancer Agents Med Chem; 2011 Nov; 11(9):794-8. PubMed ID: 21707492
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.
Evangelisti C; Evangelisti C; Buontempo F; Lonetti A; Orsini E; Chiarini F; Barata JT; Pyne S; Pyne NJ; Martelli AM
Leukemia; 2016 Nov; 30(11):2142-2151. PubMed ID: 27461062
[TBL] [Abstract][Full Text] [Related]
4. Design of Sphingosine Kinases Inhibitors: Challenges and Recent Developments.
Magli E; Corvino A; Fiorino F; Frecentese F; Perissutti E; Saccone I; Santagada V; Caliendo G; Severino B
Curr Pharm Des; 2019; 25(9):956-968. PubMed ID: 30947653
[TBL] [Abstract][Full Text] [Related]
5. Building a better sphingosine kinase-1 inhibitor.
Lynch KR
Biochem J; 2012 May; 444(1):e1-2. PubMed ID: 22533672
[TBL] [Abstract][Full Text] [Related]
6. Drugging sphingosine kinases.
Santos WL; Lynch KR
ACS Chem Biol; 2015 Jan; 10(1):225-33. PubMed ID: 25384187
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factors and sphingosine 1-phosphate signaling.
Cuvillier O; Ader I
Anticancer Agents Med Chem; 2011 Nov; 11(9):854-62. PubMed ID: 21707486
[TBL] [Abstract][Full Text] [Related]
8. The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension.
Chen J; Tang H; Sysol JR; Moreno-Vinasco L; Shioura KM; Chen T; Gorshkova I; Wang L; Huang LS; Usatyuk PV; Sammani S; Zhou G; Raj JU; Garcia JG; Berdyshev E; Yuan JX; Natarajan V; Machado RF
Am J Respir Crit Care Med; 2014 Nov; 190(9):1032-43. PubMed ID: 25180446
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine kinase 1 in cancer.
Heffernan-Stroud LA; Obeid LM
Adv Cancer Res; 2013; 117():201-35. PubMed ID: 23290781
[TBL] [Abstract][Full Text] [Related]
10. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate.
Kharel Y; Raje M; Gao M; Gellett AM; Tomsig JL; Lynch KR; Santos WL
Biochem J; 2012 Oct; 447(1):149-57. PubMed ID: 22747486
[TBL] [Abstract][Full Text] [Related]
11. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells.
Kennedy AJ; Mathews TP; Kharel Y; Field SD; Moyer ML; East JE; Houck JD; Lynch KR; Macdonald TL
J Med Chem; 2011 May; 54(10):3524-48. PubMed ID: 21495716
[TBL] [Abstract][Full Text] [Related]
12. Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.
Maiti A; Takabe K; Hait NC
Cell Signal; 2017 Apr; 32():85-92. PubMed ID: 28108260
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance.
Selvam SP; Ogretmen B
Handb Exp Pharmacol; 2013; (216):3-27. PubMed ID: 23563649
[TBL] [Abstract][Full Text] [Related]
14. Rational design of SphK inhibitors using crystal structures aided by computer.
Ding T; Zhi Y; Xie W; Yao Q; Liu B
Eur J Med Chem; 2021 Mar; 213():113164. PubMed ID: 33454547
[TBL] [Abstract][Full Text] [Related]
15. Sphk1/S1P/S1PR1 Signaling is Involved in the Development of Autoimmune Thyroiditis in Patients and NOD.H-2
Han C; He X; Xia X; Guo J; Liu A; Liu X; Wang X; Li C; Peng S; Zhao W; Zhou M; Shi X; Li Y; Li Y; Shan Z; Teng W
Thyroid; 2019 May; 29(5):700-713. PubMed ID: 30963819
[No Abstract] [Full Text] [Related]
16. Sphingosine kinase 1 as an anticancer therapeutic target.
Gao Y; Gao F; Chen K; Tian ML; Zhao DL
Drug Des Devel Ther; 2015; 9():3239-45. PubMed ID: 26150697
[TBL] [Abstract][Full Text] [Related]
17. The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy.
Zheng X; Li W; Ren L; Liu J; Pang X; Chen X; Kang D; Wang J; Du G
Pharmacol Ther; 2019 Mar; 195():85-99. PubMed ID: 30347210
[TBL] [Abstract][Full Text] [Related]
18. Regulation and functional roles of sphingosine kinases.
Alemany R; van Koppen CJ; Danneberg K; Ter Braak M; Meyer Zu Heringdorf D
Naunyn Schmiedebergs Arch Pharmacol; 2007 Feb; 374(5-6):413-28. PubMed ID: 17242884
[TBL] [Abstract][Full Text] [Related]
19. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling.
Edmonds Y; Milstien S; Spiegel S
Pharmacol Ther; 2011 Dec; 132(3):352-60. PubMed ID: 21906625
[TBL] [Abstract][Full Text] [Related]
20. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug.
Guillermet-Guibert J; Davenne L; Pchejetski D; Saint-Laurent N; Brizuela L; Guilbeau-Frugier C; Delisle MB; Cuvillier O; Susini C; Bousquet C
Mol Cancer Ther; 2009 Apr; 8(4):809-20. PubMed ID: 19372554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
